{"database": "lobbying", "table": "lobbying_activities", "rows": [[1109070, "f2ce45fe-2461-4591-9db2-f86c7edcd1e5", "Q2", "HOLLAND & KNIGHT LLP", 18466, "SHIRE PHARMACEUTICALS, INC", 2011, "second_quarter", "MED", "Advocate creation and funding of programs to support R&D for rare disease products, biosimilars and other products.  Participate in FDA stakeholder meetings re Prescription Drug User Fee program.  Met with FDA officials regarding programs to support development of products for rare diseases.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2011-07-11T11:18:04.190000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1109070"], "units": {}, "query_ms": 29.31797201745212, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}